Success Metrics

Clinical Success Rate
7.7%

Based on 1 completed trials

Completion Rate
8%(1/13)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
12(92%)

Phase Distribution

Ph phase_2
4
31%
Ph phase_3
9
69%

Phase Distribution

0

Early Stage

4

Mid Stage

9

Late Stage

Phase Distribution13 total trials
Phase 2Efficacy & side effects
4(30.8%)
Phase 3Large-scale testing
9(69.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

7.7%

1 of 13 finished

Non-Completion Rate

92.3%

12 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(1)
Terminated(12)

Detailed Status

Terminated12
Completed1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
7.7%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (30.8%)
Phase 39 (69.2%)

Trials by Status

completed18%
terminated1292%

Recent Activity

0 active trials
Showing 5 of 13
terminatedphase_2

ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)

NCT00229684
terminatedphase_3

GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus

NCT00226330
terminatedphase_3

GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes

NCT00229710
terminatedphase_2

Dose Response Study in Japanese Patients

NCT00261417
terminatedphase_3

GALLANT 8 Tesaglitazar Add-on to Metformin

NCT00251953
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT00229684Phase 2

ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)

Terminated
NCT00226330Phase 3

GALLEX 6: Study to Evaluate the Safety and Tolerability of Tesaglitazar in Patients With Type 2 Diabetes Mellitus

Terminated
NCT00229710Phase 3

GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 Diabetes

Terminated
NCT00261417Phase 2

Dose Response Study in Japanese Patients

Terminated
NCT00251953Phase 3

GALLANT 8 Tesaglitazar Add-on to Metformin

Terminated
NCT00252772Phase 3

GALLANT 2 Tesaglitazar vs. Placebo

Terminated
NCT00261352Phase 3

GALLANT 14 Tesaglitazar vs. Metformin and Fenofibrate

Terminated
NCT00252876Phase 3

GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes

Terminated
NCT00255541Phase 3

GALLANT 4 Tesaglitazar vs. Glibenclamide

Terminated
NCT00252837Phase 3

GALLANT 22 Tesaglitazar vs. Placebo

Terminated
NCT00263965Phase 2

ARAMIS: Actions of tesaglitazaR on fAt Metabolism and Insulin Sensitivity

Terminated
NCT00300105Phase 3

GALLEX 4 - Long-Term Extension Study to Evaluate Tesaglitazar Therapy in Patients With Type 2 Diabetes

Terminated
NCT00280865Phase 2

GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13